Key result
Perioperative medication discrepancies linked to ~4.2-fold higher odds of 30-day post-TAVR adverse events.
Why the study?
Multimorbidity and extensive pharmacotherapy in patients undergoing TAVR for severe symptomatic aortic stenosis pose challenges for peri-interventional medication management, and the prevalence and 30-day clinical impact of perioperative medication discrepancies required investigation.
Does the presence of perioperative medication discrepancies increase the risk of 30-day composite clinical adverse events compared to fully optimized pharmacotherapy in adult patients undergoing elective TAVR for severe aortic stenosis?
Cohort (n=120)
Yes
Does the presence of perioperative medication discrepancies increase the risk of 30-day composite clinical adverse events compared to fully optimized pharmacotherapy in adult patients undergoing elective TAVR for severe aortic stenosis?
Perioperative medication discrepancies occurred in nearly one-third of elective TAVR patients and were independently associated with a more than three-fold increased odds of 30-day composite adverse outcomes, driven notably by acute kidney injury and unplanned readmissions.
Answers are grounded in this paper and cite their sources.
Perioperative medication discrepancies were associated with higher 30-day TAVR events; leaves open whether reconciliation protocols reduce risk in trials.
Background: Transcatheter aortic valve replacement (TAVR) has become the treatment of choice for patients with high-risk or elderly severe symptomatic aortic stenosis (AS) [1]. However, the complexity of the patients' multi-morbidities and their extensive therapy poses an enormous challenge for peri-interventional pharmacotherapy [16]. This prospective observational cohort study aimed to investigate the prevalence of relevant peri-interventional medication discrepancies and their impact on 30-day outcomes following TAVR in tertiary care cardiovascular hospitals in Rawalpindi, Pakistan [17]. Methods: We prospectively enrolled 120 consecutive adult patients undergoing elective TAVR. Comprehensive standardized multi-disciplinary medication reconciliation was performed at four perioperative milestones: admission, pre-procedure, discharge and 30-day follow up [16]. Patients were divided into two groups based on the presence of any periprocedural medication optimization: those with at least one clinically significant medication discrepancy or non-indication based treatment departure vs those receiving fully optimized pharmacotherapy. The primary endpoint was a 30-day composite clinical endpoint including clinically relevant bleeding (Valve Academic Research Consortium-3 [VARC-3] criteria) [5], acute kidney injury (AKIN/KDIGO criteria) [14], stroke/transient ischemic attack (TIA), symptomatic hypotension requiring vasopressor/inotropic support, unplanned 30-day cardiac readmissions [15] and all-cause mortality. Results: Out of 120 study participants (mean age: 73.4 ± 6.2 years; 43.3% female), 38 patients (31.7%) had at least one clinically significant medication discrepancy while 82 patients (68.3%) underwent fully optimized pharmacotherapy. The primary composite outcome occurred in 28 of the total patients (23.3%). Patients in the medication discrepancy group had a substantially higher incidence of 30-day composite adverse events than patients in the optimized pharmacotherapy group (42.1% vs. 14.6%; Odds Ratio [OR]: 4.23, 95% Confidence Interval [CI]: 1.76 to 10.18, p < 0.001). Specifically, higher rates of acute kidney injury (18.4% vs. 4.9%; p = 0.024), and 30-day unplanned hospital readmissions (21.1% vs. 6.1%; p = 0.019) were observed in the medication discrepancy group. Perioperative medication discrepancy was independently associated with 30-day composite adverse outcomes as demonstrated by multivariable logistic regression analysis (adjusted OR: 3.64, 95% CI: 1.42 to 9.32, p = 0.007). Conclusion: Perioperative medication discrepancies are highly prevalent among TAVR candidates in South Asian clinical practice and significantly increase early morbidity and unplanned hospital readmissions [17]. Systematic clinical pharmacy-led medication reconciliation and strict adherence to indication-based antithrombotic guidelines represent essential strategies to optimize periprocedural safety and enhance post-TAVR recovery [16].
No takes yet. Share an insight, caveat, or question.
Sarmad et al. (2026) conducted a cohort in Severe aortic stenosis undergoing elective TAVR (n=120). Perioperative medication discrepancy or non-indication based treatment departure vs. Fully optimized pharmacotherapy was evaluated on 30-day composite clinical endpoint of clinically relevant bleeding (VARC-3), acute kidney injury (AKIN/KDIGO), stroke/TIA, symptomatic hypotension requiring vasopressor/inotropic support, unplanned 30-day cardiac readmissions, and all-cause mortality (OR 4.23, 95% CI 1.76-10.18, p=<0.001). Perioperative medication discrepancies increased 30-day composite adverse events after TAVR compared to optimized pharmacotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: